GO
Loading...

Eli Lilly and Co

More

  • Final Glance: Pharmaceuticals companies Thursday, 11 Dec 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 35 or. 5 percent, to $73.11. Bristol-Myers Squibb Co. rose$. 40 or. 7 percent, to $59.68. Hospira rose $2.69 or 4.5 percent, to $62.08.

  • Midday Glance: Pharmaceuticals companies Thursday, 11 Dec 2014 | 1:19 PM ET

    Baxter International Inc. rose$. 48 or. 7 percent, to $73.24. Bristol-Myers Squibb Co. rose$. 93 or 1.6 percent, to $60.21. Hospira rose $3.10 or 5.2 percent, to $62.49.

  • Early Glance: Pharmaceuticals companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Baxter International Inc. rose$. 59 or. 8 percent, to $73.35. Bristol-Myers Squibb Co. rose$. 71 or 1.2 percent, to $59.99. Hospira rose $2.35 or 4.0 percent, to $61.74.

  • Final Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Baxter International Inc. fell $1.03 or 1.4 percent, to $72.76. Bristol-Myers Squibb Co. fell$. 69 or 1.2 percent, to $59.28. Hospira fell$. 97 or 1.6 percent, to $59.39.

  • Midday Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $73.40. Bristol-Myers Squibb Co. rose$. 06 or. 1 percent, to $60.03. Hospira fell$. 11 or. 2 percent, to $60.25.

  • Early Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Baxter International Inc. fell$. 08 or. 1 percent, to $73.71. Hospira fell$. 56 or. 9 percent, to $59.80. Eli Lilly& Co. fell$. 56 or. 8 percent, to $71.65.

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Final Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Baxter International Inc. fell$. 33 or. 4 percent, to $73.79. Bristol-Myers Squibb Co. fell$. 70 or 1.2 percent, to $59.97. Hospira rose$. 24 or. 4 percent, to $60.36.

  • Midday Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Baxter International Inc. fell$. 74 or 1.0 percent, to $73.38. Bristol-Myers Squibb Co. fell$. 92 or 1.5 percent, to $59.75. Hospira fell$. 11 or. 2 percent, to $60.01.

  • Early Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Baxter International Inc. fell$. 61 or. 8 percent, to $73.51. Bristol-Myers Squibb Co. fell$. 87 or 1.4 percent, to $59.80. Hospira rose$. 74 or 1.2 percent, to $60.86.

  • Final Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 10 or. 1 percent, to $74.12. Bristol-Myers Squibb Co. rose$. 02 or percent, to $60.67. Hospira rose$. 02 or percent, to $60.12.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 1:20 PM ET

    Baxter International Inc. fell$. 01 or percent, to $74.21. Bristol-Myers Squibb Co. rose$. 18 or. 3 percent, to $60.83. Hospira fell$. 09 or. 1 percent, to $60.01.

  • Early Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 10:22 AM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $74.35. Bristol-Myers Squibb Co. rose$. 13 or. 2 percent, to $60.78. Hospira fell$. 22 or. 4 percent, to $59.88.

  • Dec 2- Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study. Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs,...

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...

  • Lilly, Boehringer revise terms of diabetes drugs alliance Wednesday, 29 Oct 2014 | 8:55 AM ET

    Oct 29- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries. Under the alliance signed in 2011, the companies had agreed to develop and market diabetes drugs together. Boehringer and Eli Lilly said on Wednesday that they would continue joint development and marketing of...

  • Early Movers: DD, PFE, AET, TWTR, MSG, WMT & more Tuesday, 28 Oct 2014 | 8:07 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *Fujifilm extends gains, but fund manager says its core business uncertain. It helped drive up Seven& i Holdings Co and Aeon Co 1.0 percent and 0.6 percent, respectively. Outperforming the market was Takeda Pharmaceutical Co, which rose 2.6 percent after a U.S. judge slashed a $9 billion punitive damages award to $36.8 million against it and Eli Lilly& Co over their...

  • Oct 27- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly& Co over their Actos diabetes drug. District Judge Rebecca Doherty in Louisiana in a court filing granted a motion from the drugmakers to reduce the $9 billion in combined punitive damages awarded earlier this year.